Background High interindividual variability in plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, may lead to suboptimal drug concentration.
Abstract
Background High interindividual variability in plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, may lead to suboptimal drug concentration.
Objective Using a population pharmacokinetic approach, we aimed to characterize the genetic and non-genetic sources of variability affecting risperidone and 9-hydroxyrisperidone pharmacokinetics, and relate them to common side effects. Methods Overall, 150 psychiatric patients (178 observations) treated with risperidone were genotyped for common polymorphisms in NR1/2, POR, PPARa, ABCB1, CYP2D6 and CYP3A genes. Plasma risperidone and 9-hydroxyrisperidone were measured, and clinical data and common clinical chemistry parameters were collected. Drug and metabolite concentrations were analyzed using non-linear mixed effect modeling (NONMEM Ò
. Correlations between trough concentrations of the active moiety (risperidone plus 9-hydroxyrisperidone) and common side effects were assessed using logistic regression and linear mixed modeling.
Results The cytochrome P450 (CYP) 2D6 phenotype explained 52 % of interindividual variability in risperidone pharmacokinetics. The area under the concentration-time curve (AUC) of the active moiety was found to be 28 % higher in CYP2D6 poor metabolizers compared with intermediate, extensive and ultrarapid metabolizers. No other genetic markers were found to significantly affect risperidone concentrations. 9-hydroxyrisperidone elimination was decreased by 26 % with doubling of age. A correlation between trough predicted concentration of the active moiety and neurologic symptoms was found (p = 0.03), suggesting that a concentration [40 ng/mL should be targeted only in cases of insufficient, or absence of, response. Conclusions Genetic polymorphisms of CYP2D6 play an important role in risperidone, 9-hydroxyrisperidone and active moiety plasma concentration variability, which were associated with common side effects. These results highlight the importance of a personalized dosage adjustment during risperidone treatment.
Introduction
Risperidone, an atypical antipsychotic, is widely prescribed in adults, but also in pediatric and elderly patients. In addition to overall good therapeutic efficacy, several adverse events have been described during risperidone treatment, including neurologic symptoms, hyperprolactinemia, weight gain, and insulin resistance, some of which have been shown to be dose-and plasma concentration-dependent [1] . High interindividual variability in plasma concentrations of risperidone can be explained by genetic (i.e. cytochrome P450 [CYP] 2D6) and non-genetic (i.e. age, sex or renal function) factors [2, 3] . In humans, risperidone undergoes an important first-pass effect and is metabolized mainly by CYP2D6 [4, 5] , with a contribution of CYP3A, as shown by several interaction studies with CYP3A inducers [6, 7] or inhibitors [8, 9] . The main metabolite of risperidone, 9-hydroxyrisperidone [4] , is mainly eliminated by the kidneys [10] . Risperidone and 9-hydroxyrisperidone are generally considered to have the same pharmacodynamic properties, and the sum of both substances defines the 'active moiety' [11] . The CYP2D6 genetic polymorphism has been well-described, with the existence of four predicted phenotypes: poor (PM), intermediate (IM), extensive (EM) or ultrarapid metabolizers (UM) [12] . A growing number of reports underline the impact of CYP2D6 polymorphism on risperidone and 9-hydroxyrisperidone pharmacokinetics, and on clinical outcomes. A significant median increase of steady-state risperidone concentrations in PM patients compared with other genotypes was indeed found in a Caucasian schizophrenic cohort [13] . Moreover, discontinuation rates due to adverse reactions were found to be higher in PM carriers compared with IMs, EMs or UMs [14] . CYP3A is the combination of three isoforms, CYP3A4, CYP3A5 and CYP3A7 with overlapping activities. Several genetic polymorphisms of CYP3A isoforms have been described, such as the 3A5*3 variant resulting in a loss of CYP3A5 protein synthesis, or the CYP 3A4*22 allele resulting in a decrease of CYP3A4 messenger RNA (mRNA) expression, polymorphisms which have been associated with differences in clinical outcome for drugs such as simvastatin and ciclosporin (cyclosporin) [15, 16] . A few studies investigated the effect of CYP3A polymorphism on risperidone plasma concentration, with opposing results [17, 18] . This may be partly due to the fact that genotyping methods allow the capture of only a small extent of the variability of CYP3A activity [19] [20] [21] . Mutations of other non-CYP genes, such as the CYP oxidoreductase (POR), which provides the necessary electrons for CYP activity, have also been found to influence CYP activity. The POR*28 allele was found to be associated with decreased CYP3A activities [22] . In addition, many nuclear receptors such as the pregnane X receptor (encoded by the NR1/2 gene) or the peroxisome proliferator-activated receptor-a (PPARa) may regulate the expression of genes involved in drug disposition, such as CYP450 and ABCB1, which encodes the permeability glycoprotein (Pgp), a drug transporter [23] . In vitro experiments identified several single-nucleotide polymorphisms (SNPs) in the promoter region of NR1/2, which may affect CYP3A expression [24, 25] . Recent studies also showed associations between NR1/2 genotypes and an increased risk of delayed graft rejection [26] or side effects during treatment with long-acting risperidone [27] .
Risperidone treatment can induce neurologic side effects such as akathisia, rigidity or tremor. However, conflicting results were obtained in several studies examining the relationship between risperidone or 9-hydroxyrisperidone concentrations and neurological toxicity [28] [29] [30] [31] . Hyperprolactinemia is also a common issue for patients receiving risperidone. It may induce sexual dysfunction and, in the long-term, be a risk factor for cardiovascular disorders and decreased bone mineral density [32] . Several reports have shown a relationship between plasma concentrations of risperidone or 9-hydroxyrisperidone and prolactin [33, 34] .
To date, several population pharmacokinetic studies on risperidone in psychiatric populations have been published indicating an influence of carbamazepine on the plasma concentration of the active moiety [35] , an age-related decrease of 9-hydroxyrisperidone clearance and a decrease in risperidone clearance in male patients and in patients receiving paroxetine or fluoxetine treatment [36] . One study found average active moiety plasma concentration was higher in CYP2D6 PMs, as well as an association between active moiety and dystonia and parkinsonism [28] .
The objectives of the present study were to characterize the population pharmacokinetics of risperidone, 9-hydroxyrisperidone and/or the active moiety in a cohort of psychiatric patients, to study genetic and non-genetic sources of variability and identify a threshold level associated with common side effects.
Methods

Study Design and Participants
Participants were selected from three observational pharmacogenetic studies whose main inclusion criteria were the prescription of second-generation antipsychotic drugs. Thirty-five patients were included in the first cross-sectional study, as detailed previously [37] [38] and Salazar-Corcoran [39] formulas), comedications, including possible co-prescription of a second-generation antipsychotic (classified as strong or moderate CYP2D6 inhibitors, CYP3A4 inducers, and Pgp inhibitors or inducers), and several genetic polymorphisms [40] [41] [42] [43] [44] [45] . Side effects for the 78 subjects from the longitudinal study were classified according to the Udvalg for Kliniske Undersøgelser (UKU) side effect rating scale and categorized as absent, light, medium or severe [46] . All investigated side effects were reported on the same day that the blood samples were drawn for pharmacokinetic measurements. They were classified into five groups: neurologic (akathisia, rigidity and tremor), gastrointestinal (constipation, increased/reduced salivation and nausea), cardiovascular (hypertension, hypotension and lower-extremity edema), central nervous system (asthenia, sleepiness) and sexual side effects (diminished sexual desire, ejaculatory dysfunction, erectile dysfunction and orgasmic dysfunction). All three studies were approved by local Ethics Committees (Geneva and Lausanne), and written informed consent (for genetic analysis also) was obtained from all patients or from their legal representatives.
Plasma Concentration Determinations
All blood samples were collected in EDTA-containing tubes. After centrifugation, plasma samples were stored at -20°C until routine analysis. Risperidone concentrations were determined by a high-performance liquid chromatography-mass spectrometry (HPLC-MS) method, as described previously [27] . Prolactin, creatinine, ASAT and ALAT concentrations were determined by immunoassay on an Abbott Axsym system (Abbott GmbH, Wiesbaden, Germany). With regard to prolactin, only blood samples drawn between 8:00 a.m. and 10.30 a.m. were analyzed.
Genotyping
Genomic DNA was extracted from EDTA blood samples using the FlexiGene DNA extraction kit (Qiagen Instruments AG, Hombrechtikon, Switzerland) according to the manufacturer's protocol. The following SNPs were detected by real-time polymerase chain reaction (PCR) according to the manufacturer's instructions (ABI PRISM 7000; Applied Biosystems, Rotkreuz, Switzerland): CYP2D6*3 (rs35742686), CYP2D6*4 (rs3892097), CYP2D6*6 (rs5030655), CYP3A4*1B (rs2740574), CYP3A4 intron 7
, and ABCB1 1236C[T (rs1128503). Detection of duplication/multiplication of CYP2D6*xN was performed by long PCR and CYP2D6*5 gene deletion (Hs0001001_cn) was analyzed using TaqMan copy number assay, as previously described [47] . In each set of analyses, control DNAs with known genotypes were included.
Model-Based Pharmacokinetic Analysis
Structural and Error Model
Since metabolite formation occurs rapidly via first-pass metabolism and systemic biotransformation of risperidone [4] , a simultaneous parent drug/metabolite pharmacokinetic analysis was conducted. A one-compartment model with first-order absorption and elimination was used for both risperidone and 9-hydroxyrisperidone, using a linear conversion from risperidone to 9-hydroxyrisperidone ( Fig. 1) . In order to account for presystemic metabolism, the fraction (FR) of risperidone dose converted during the first-pass effect was estimated. The absorption rate constants k 12 and k 13 were defined as (1-FR)*k a and FR*k a , respectively, with k a representing the total absorption rate constant. Due to the limited amount of measurements in the absorption phase, k a was fixed to 3.1 h -1 to achieve risperidone peak plasma concentration as reported in the literature [35, 36, 48] . Since risperidone was administered orally, risperidone and 9-hydroxyrisperidone pharmacokinetic parameters represent apparent values. Owing to identifiability problems, both compounds were assumed to have the same apparent volume of distribution (V). Interpatient variability of all the pharmacokinetic parameters, with the exception of FR, was described by exponential errors following a log-normal distribution. The logit of FR was used to constrain individual FR to vary between 0 and 1, and its interindividual variability calculated as previously reported [49] . Correlations between pharmacokinetic parameters were investigated. Finally, several error models were compared to describe the intrapatient (residual) variability for both drug and metabolite. The correlation between risperidone and 9-hydroxyrisperidone concentration measurements was tested using the L2 function in nonlinear mixed effect modeling (NONMEM Ò ).
Covariate Model
The covariate analysis was performed using a stepwise insertion/deletion approach. First, visual inspection of the correlation between post hoc individual estimates of the pharmacokinetic parameters and the available factors was conducted. Potentially influential covariates were then incorporated sequentially into the model using linear or non-linear functions as appropriate (categorical variables were coded as 0 and 1, a fixed effect was associated with each of the ethnic groups within the population, and continuous covariates were centered on their median value or to 80 ml/min for CL creat ). Sequential analysis of the impact of genetic polymorphisms on pharmacokinetic parameters was conducted categorizing patients into genotypic groups or, in the case of CYP2D6, into predicted phenotypic groups. Parameter values were then estimated for each genotypic/phenotypic group (rich model) or for further regrouped (reduced model) subpopulations.
Parameter Estimation and Model Selection
Risperidone and 9-hydroxyrisperidone data were fitted by use of the first-order conditional estimation (FOCE) method with interaction using NONMEM Ò version 7.2 [50] with PsN-Toolkit version 3.5.3 [51] . Concentrations below the quantification limit of the assay were replaced by LOQ/2 (M6 method [52] ). The log-likelihood ratio test, based on changes in the objective function value (OFV) [DOFV] , was employed to discriminate between hierarchical models. Since a DOFV between any two models approximates a Chi-square distribution, a decrease of the objective function was considered statistically significant if it exceeded 3.84 (p \ 0.05) or 6.63 (p \ 0.01) for one additional parameter in the model building and backward deletion steps, respectively. Diagnostic goodness-of-fit plots and precision of the pharmacokinetic parameters were also used to assess the reliability of the results.
Model Evaluation and Assessment
Final model stability was assessed by means of the bootstrap method implemented in PsN [51] Compartmental model used to describe risperidone and 9-hydroxyrisperidone plasma concentration-time profiles. FR fraction of the dose converted into metabolite, CL RISP mean apparent risperidone clearance, CL 9OHR mean apparent 9-hydroxyrisperidone clearance, V mean apparent volume of distribution, k a total absorption rate constant, k 12 absorption rate constant from depot to risperidone compartment, k 13 absorption rate constant from depot to 9-hydroxyrisperidone compartment, k 23 metabolic rate constant, k 20 risperidone elimination rate constant, k 30 9-hydroxyrisperidone elimination rate constant prediction distribution errors (NPDEs) [53] . In addition, visual predictive checks stratified on the CYP2D6 phenotype were performed for model validation. Figures were generated using GraphPad Prism Ò , version 6.00 for Windows (GraphPad Software, San Diego, CA, USA).
Simulations
Simulations of 1000 individuals for each CYP2D6 phenotype based on the final model with variability were conducted to derive the average AUC from time zero to 24 h (AUC 24 ) with 95 % prediction intervals (PI 95% ) for risperidone, 9-hydroxyrisperidone and the active moiety (AUC RISP , AUC 9OHR , AUC active moiety = AUC RISP ? AUC 9OHR ). Differences in average AUC 24 between metabolic groups were analyzed by one-way analysis of variance (ANOVA) using the Bonferroni correction (Stata version 12; StataCorp LP, College Station, TX, USA).
Concentration-Adverse Events Relationship
The relation between UKU-reported side effects and the final model-predicted trough plasma concentration of risperidone, 9-hydroxyrisperidone and active moiety (C min-RISP , C min-9OHR , C min-active moiety ) were investigated by logistic regression analyses. Side effect ratings were dichotomized in absence versus presence while including the side effect reported at the last visit. The relation between prolactin and C min-RISP , and C min-9OHR and C minactive moiety was investigated by linear mixed effect modeling using the 'nlme' package of R [54] . Statistically significant results were considered as p B 0.05.
Results
Demographic
A total of 178 sample concentrations were available from 150 included patients who were receiving risperidone at a total dose ranging from 0.5 to 8 mg daily, administered either once (n = 21 in the morning, n = 106 in the evening) or twice (n = 51) daily. All concentrations were measured in steady-state conditions, and 47 concentrations were on trough. The measured concentrations for drug and metabolite ranged between 0 and 62 ng/mL and 0.5 and 69 ng/mL, respectively. A median prolactin concentration of 31 and 85 lg/L was observed in male and females, respectively. Three patients treated with haloperidol, levomepromazine and pipamperone, as well as two patients with a prolactin level of 345 lg/L (previous coadministration of pipamperone) and 238 lg/L (breast cancer) were withdrawn from the prolactin analysis. Other characteristics of the study population are presented in Table 1 . In our population with completed UKU rating scale, 43, 40, 7, 45 and 30 % of patients reported neurologic, autonomic, cardiovascular, psychic and sexual dysfunction side effects, respectively. Nine patients were withdrawn from the side effect analysis (biperiden = 11, haloperidol = 5, levomepromazine = 1, pipamperone = 1, with some patients receiving more than one of these four drugs at the same time). Numbers and frequencies of all side effects are described in electronic supplementary eTable 1. For all Caucasian patients, genotype frequencies were in Hardy-Weinberg equilibrium. Genetic characteristics of patients are presented in electronic supplementary eTable 2.
Structural Model
The model illustrated in Fig. 1 adequately describes risperidone and 9-hydroxyrisperidone data; however, because of the important presystemic metabolism, the metabolic rate constant (k 23 ) could not be properly estimated and, therefore, was fixed to 0. Association of interindividual variability on FR (DOFV = -22.2; p = 2.4Á10 -6 ) in addition to risperidone clearance (CL RISP ) markedly improved the model fit, which was further improved by the inclusion of an interpatient variability on 9-hydroxyrisperidone clearance (CL 9OHR ) [DOFV = -38.3; p = 6.1Á10 -10 ) but not on V (DOFV = -3.6; p = 0.06). Allowing for a correlation between FR and CL 9OHR (DOFV = -54.9; p = 1.3Á10 -13 ) and, successively, between FR and CL RISP (DOFV = -7.5; p = 6.3Á10 -3 ) resulted in a noticeable improvement of the model fit. Residual intrapatient variability on both risperidone and 9-hydroxyrisperidone was satisfactorily described using a proportional error model. Drug and metabolite concentration measurements were found to be significantly correlated (DOFV = -6.3; p = 0.01). The parameter estimates with interpatient variability (CV%) of the basic pharmacokinetic model were a CL RISP of 3.8 L/h (42 %), a V of 290 L, a CL 9OHR of 5.8 L/h (44 %), an FR of 89 % (19 %) and a k a fixed to 3.1 h -1 .
Covariate Analysis
Univariate analyses testing the influence of the non-genetic covariates on risperidone pharmacokinetics revealed a significant impact of age and sex on both FR (DOFV B -6.5; p B 0.01) and CL 9OHR (DOFV B -8.2; p B 4.0Á10 -3 ). All remaining demographic, environmental and physiologic characteristics were not associated with the drug pharmacokinetics (DOFV [ -2.7; p [ 0.10). Because of the high correlation between CL 9OHR and FR, only the effects of sex g Prolactin plasma levels higher than 50 lg/L for women and higher than 40 lg/L for men are considered as high and age on CL 9OHR were retained for further investigations (DOFV [ -2.2; p [ 0.14). Multivariate analyses showed that only age influenced CL 9OHR (DOFV = -2.9; p = 0.08 with respect to the model with age and sex on CL 9OHR ). A decrease of 27 % in CL 9OHR with doubling of age compared with the median population age of 39 years was observed.
Coadministration of strong and moderate Pgp and CYP2D6 inhibitors affected both FR (DOFV B -6.1; p B 0.01) and CL RISP (DOFV B -4.0; p B 0.05), while CYP3A4 did not impact the pharmacokinetics of risperidone (DOFV C -1.0; p C 0.32). Multivariate analyses allowed the effect of inhibitors on CL RISP to be discarded, while the effect of inhibitors on FR was able to be retained (DOFV C -0.8; p C 0.37). Only CYP2D6 inhibitors on FR were finally retained (DOFV = -1.8; p = 0.19 with respect to the model with both CYP2D6 and Pgp inhibitors on FR), and were found to decrease FR by 5 and 9 % if categorized as moderate or strong inhibitors, respectively.
The effect of common polymorphisms in CYP2D6, CYP3A4/5/7, POR, NR1/2 and ABCB1 on CL RISP , CL 9OHR and FR showed that the predicted CYP2D6 phenotypes had by far the most important influence on FR (DOFV = -82.6; p = 8.5Á10
-18 ), CL RISP (DOFV = -31.8; p = 5.8Á10 -7 ) and CL 9OHR (DOFV = -30.3; p = 1.2Á10 -6 ). Carriers of the CYP3A4 rs35599367 GA allele were found to have a CL 9OHR 30 % lower than GG individuals (DOFV = -7.0; p = 8.0Á10
-3 ). NR1/2 rs1523130 and NR1/2 rs2276707 polymorphisms affected CL RISP and FR, respectively (DOFV = -8.7, p = 0.01; and DOFV = -7.5, p = 0.02). A reduced model in which NR1/2 rs1523130 CT and TT or NR1/2 rs2276707 CT and TT individuals were grouped also characterized the influence of PXR rs1523130 on CL RISP or NR1/2 rs2276707 on FR (DOFV C0.01; p = 1.0), suggesting a recessive effect of the gene. CL RISP was found to be 33 % higher in NR1/2 rs1523130 CT/TT than in CC individuals, while FR was 6 % higher in NR1/2 rs2276707 CT/TT with respect to CC individuals. No other genetic polymorphisms were significant (DOFV C -5.7; p C 0.06). Multivariate combination of the influential genetic polymorphisms showed that only the CYP2D6 phenotype remained significant. Moreover, the influence of this phenotype on FR captured its previously observed effect on both CL RISP and CL 9OHR (DOFV C -3.6; p C 0.31), and markedly stabilized the model fit, allowing for the estimation of k 23 . No statistically significant difference was observed between CYP2D6 UM and EM compared with the rich model in which an FR was assigned to each CYP2D6 phenotypic group (DOFV = 0.10; p = 0.76).
Estimated average FRs were 92 % for EM/UM (n = 99), 86 % for IM (n = 41) and 19 % (n = 10) for PM individuals. CYP2D6 polymorphisms and inhibitors on FR and age on CL 9OHR remained statistically significant in the multivariate analysis and backward deletion step. The estimated average fraction of risperidone dose converted into 9-hydroxyrisperidone was 93, 85 and 8.8 % for EM/ UM, IM and PM patients, respectively, suggesting that IMs and PMs have decreased 8 and 91 % in FR, respectively, compared with EM/UM individuals. Coadministration of moderate and strong CYP2D6 inhibitors decreased FR by 4 and 19 %, respectively. Predicted CYP2D6 phenotypes and CYP2D6 inhibitor intake explained, altogether, 52 % of initial FR interpatient variability. Moreover, our results show that doubling of age, with respect to the median age of the population, reduced CL 9OHR by 26 %, explaining 26 % of its interpatient variability. The final model parameter estimates and bootstrap estimations are given in Table 2 . The model was considered reliable since the obtained parameter estimates lay within the bootstrap CI 95% . NPDE analysis confirmed that the model adequately described the observed data. Dose-normalized CYP cytochrome P450, PI 95% 95 % prediction interval, IM intermediate metabolizer, EM extensive metabolizer, UM ultrarapid metabolizer, PM poor metabolizer concentration-time plots of risperidone and 9-hydroxyrisperidone with PI 95% for EM/UM and PM patients with a population median age are shown in Fig. 2 .
Simulations
Model-based simulations were performed to estimate and compare AUC RISP , AUC 9OHR and AUC active moiety for individuals characterized by different CYP2D6 metabolic strengths (Fig. 3) 
Concentration-Adverse Event Relationship
No associations were observed between CYP2D6 predicted phenotype and/or inhibitor with reported side effects. Autonomic, cardiovascular, psychic and sexual side effects were not associated with C min-active moiety (electronic supplementary eFig. 1); however, the presence of neurologic symptoms was associated with C min-active moiety (p = 0.03) (Fig. 4) . In particular, only the severity of tremor was associated with C min-active moiety (p = 0.01) [electronic supplementary eFig. 2]. By correcting for age and sex, an increase in C min-active moiety was associated with developing neurologic symptoms (p = 0.03). In the neurologic group, an increase in C min-active moiety was associated with tremor and akathisia (p = 0.01 and p = 0.02, respectively) ( rigidity. Logistic regression plot indicates a 70 % or more probability of developing neurologic symptoms at C min-active moiety 40 ng/mL and higher (Fig. 4) .
Prolactin was found to be more elevated in PM and IM, or in the presence of CYP2D6 inhibitors, but only in women (p = 0.04) [electronic supplementary eFig. 3]. Mixed linear model corrected by age revealed a correlation between prolactin concentration and C min-9OHR (b = 2.36 lg/L, P adjusted = 0.04) and C min-active moiety (b = 2.03 lg/L, P adjusted = 0.03) in women (Table 4) . No significant associations were observed between prolactin concentrations and sexual dysfunction side effects in both sexes (data not shown).
Discussion
To our knowledge, this is the first population pharmacokinetic study that included a broad range of patients of different ages, with an extensive analysis of genetic markers, and with a concentration-effect analysis. CL RISP and CL 9OHR were estimated to be 4.6 and 6 L/h, respectively, which is in the same range of previously published studies [28, 35] . A first-pass effect of 92 % for EM/UM patients and 19 % for PM patients was calculated in the present study, highlighting the strong influence of CYP2D6 genetic polymorphism on first-pass effect. Other non-CYP2D6 genetic determinants were found to significantly influence risperidone and/or 9-hydroxyrisperidone disposition in univariate analysis and, although withdrawn in the multivariate model, these results must be further investigated in larger population samples. A decrease of 4 and 19 % in the first-pass effect upon coadministration of weak (methadone, citalopram, duloxetine, venlafaxine and sertraline [40] ) and strong (levomepromazine, haloperidol, paroxetine or fluoxetine [40] ) CYP2D6 inhibitors was observed. These results are in agreement with studies showing that paroxetine increases the plasma concentration of risperidone [55] , that patients with paroxetine or levomepromazine as co-medications have a significantly higher risperidone concentration-dose ratio than patients without co-medication [56] , and that the prescription of fluoxetine as co-medication increases the active moiety by 50-75 % [57, 58] . One can mention that there are discrepant data on the inhibition potential of haloperidol, with some defining it as a strong inhibitor [40] and others defining it as a weak inhibitor [41] ; however, no differences were observed when comparing the pharmacokinetic model with haloperidol classified as a strong versus weak CYP2D6 inhibitor (data not shown).
As demonstrated in several other studies [28, [59] [60] [61] , CYP2D6 activity plays the most important role in risperidone disposition, resulting in low concentrations of risperidone and high concentrations of 9-hydroxyrisperidone in patients with high CYP2D6 activity. Simulations showed that CYP2D6 genotype affects risperidone and 9-hydroxyrisperidone exposures with a direct influence on the active moiety. Thus, although no statistical differences were found in AUC active moiety between EM/UMs and IMs, a significant difference was found between PMs and EM/ UM/IM. A non-significant increase of AUC active moiety was observed in a single-dose study of healthy volunteers [62] . Although some studies found no differences in steady-state active moiety plasma concentration between CYP2D6 genotypes [13, 30, 60, 63] , an increase of 27 % in the active moiety plasma concentration was observed in another study [59] , which is in agreement with the present findings. Negative results could be due to small patient samples and insufficient numbers of PM patients. In addition, an influence of PM status on the active moiety concentrations is in agreement with the results of a study including 325 stabilized outpatients receiving risperidone, with PMs having a 3.1-fold higher risk of moderate to severe adverse drug reactions [14] .
By reflecting renal function, age is a well-known factor affecting CL 9OHR [2, 4, 36] . Nevertheless, no significant [29] [30] [31] . In the present study, C min-active moiety was significantly associated with akathisia and tremor, combined with rigidity. Interestingly, in a previously published population pharmacokinetic study, akathisia was not associated with average plasma concentration [28] . The C min of 9-hydroxyrisperidone was not found to be associated with any neurologic side effects, which could be tentatively explained by a lower affinity to D 2 receptors and a higher affinity to 5-HT 2A receptors compared with risperidone [65] . This is also in agreement with prospective studies reporting a decrease of neurologic symptoms after switching from risperidone to 9-hydroxyrisperidone (paliperidone) [66, 67] , although more studies are needed to validate the strategy of switching from risperidone to paliperidone in case of poor tolerability. Logistic regression analysis indicated that a C min-active moiety over 40 ng/ mL is associated with a more than 70 % risk of developing neurologic symptoms (Fig. 3) . Because 40 ng/mL is the median value of the proposed therapeutic range (20-60 ng/ mL) [68] , this suggests that the upper range of the therapeutic window should only be targeted in cases of insufficient, or absence of, response.
Prolactin concentration was associated with 9-hydroxyrisperidone C min in women. 9-hydroxyrisperidone is characterized by a longer half-life and higher hydrophilicity than risperidone, which is important considering that the pituitary lies outside the blood-brain barrier [34, [69] [70] [71] . Estrogens lead to an increase in lactotrophic cells in the pituitary and a decrease of D 2 receptor synthesis [72] , which may confer to women a higher sensibility to prolactin release induced by anti D 2 drugs [73] .
There are several limitations to the present study. No effect of CYP3A inducers and Pgp inhibitors as co-medication could be observed, which may be explained by an insufficient number of patients receiving such treatments. Second, side-effect scales were only recorded for the longitudinal study in which scales were missing for several patients, which could therefore lead to a reporting bias. Strengths of the present study include a naturalistic design, multiple observations over time, and a broad age and BMI range which may therefore increase the clinical validity of the pharmacokinetic results. In addition, patients with co-medications known to induce neurologic symptoms or to increase prolactin concentration were excluded from the pharmacodynamic analysis.
Conclusions
This analysis underlines the importance of CYP2D6 activity status on first-pass effect and age on metabolite clearance. Due to this important variability, therapeutic drug monitoring should be used to adjust drug dosage with the aim of targeting, as a first step, and after careful evaluation of the clinical situation, the lower therapeutic window range (20-40 ng/mL), which is less associated with neurologic side effects. These results highlight the importance of a personalized approach, including both genetic (i.e. before introduction of treatment) and therapeutic drug monitoring (during treatment) data, when treating patients with risperidone.
